Ignite Creation Date:
2025-12-24 @ 11:34 PM
Ignite Modification Date:
2026-02-27 @ 7:05 PM
Study NCT ID:
NCT02340156
Status:
TERMINATED
Last Update Posted:
2021-03-03
First Post:
2014-12-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
Sponsor:
SynerGene Therapeutics, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SGT53-02-2
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None